SNY
Sanofi ADR
$43.16+3.68%
Setup
Near pivot
Buy Zone
$43.48-$45.65
Sector
Drug Manufacturers - General
Industry
Drug Manufacturers - General
27
Recommendation
Avoid
Avoid
Too many CANSLIM criteria failing.
SNY chart
Loading chart…
Overall Quality27
RS Rating
21
relative strength
Fundamentals
53
Weak fund-Q
Volume Demand
82
+10% vs avg
Technical Setup
50
4/8 checks
Industry/Theme
91
Drug Manufacturers - General
Trade Plan
Avoid
Entry
$43.48
Entry Zone
$43.48-$45.65
Stop / Risk
$40
RS Rating
21
Volume confirmed
Yes
Targets
$52.18 / $54.35
Breakout · IBD Setup
2 ✓ 6 ✗
Entry $43.48–$45.65Stop $40Target $52.18 / $54.35
Market regimeRange
Quality27
RS Rating21
Above 50-MA-1.49%
Above 200-MA-8.02%
VolumeConfirmed
In Buy ZoneNo
Not extendedOK
Invalidation · Close below stop
How this came together
27
MarketRange
SetupNear pivot
ConfidenceExperimental · not backtested
Fund-Q53 · Weak
StatusAvoid
Stock Data
52-Week Range41 – 53
Price % Chg YTD-10.94%
Price % Chg 4wk0.84%
50-Day Avg Vol3.1 Mil
P/E Ratio18.0
Market Cap$103B
SectorHealthcare
IndustryDrug Manufacturers - General
Company Fundamentals
EPS % Chg (Qtr)-29.64%
Sales % Chg (Qtr)28.69%
EPS Growth 5y-15.52%
Sales Growth 5y3.69%
Annual ROE6.76%
Gross Margin65.9%
Operating Margin26.1%
Net Margin11.81%
Debt / Equity0.28
Setup levels
Current price
$43.16
Pivot
$43.48
Distance to buy
-18.1%
52-week range
40.89-52.68
Trigger evidence
No active trigger evidence available.
Pattern levels: pivot 43.48
Financial health checks
3/5
Return on equity above 15%
ROE 6.76%
Net margin above 10%
Net margin 11.81%
EPS growing quarter on quarter
EPS q/q -29.64%
Sales growing quarter on quarter
Sales q/q 28.69%
Debt to equity below 1.0
D/E 0.28
Key metrics
Finviz snapshot · value vs. sector median (≥5 peers)
Annual ROE6.76%
vs sector -16.2%
Net margin11.81%
vs sector -7.5%
Gross margin65.9%
vs sector -5.7%
EPS growth q/q-29.64%
vs sector -48.8%
Sales growth q/q28.69%
vs sector +7.5%
Debt / equity0.28
vs sector -0.44
Business quality
53
GradeWeak
EPS rating18
P/E18.0
Market cap$103B
IndustryDrug Manufacturers - General
Technical checks
Über 50-MA
Fail
Über 200-MA
Fail
RS-Linie auf neuem Hoch
Fail
Volumen bestätigt
Pass
In Kaufzone
Fail
Nicht überextended
Pass
Über 21-EMA
Pass
Volumen gesund
Pass
IBD / source mentions
No recent IBD mention found for this ticker.
Signal history
Added to list
2026-06-25
Trigger date
—
Days on list
9
Data sources: internal CANSLIM engine · Finviz snapshot · TradingView chart. Not investment advice.